Olfr678, encoded by the Or52e5 gene in Mus musculus, is part of the olfactory receptor family, which is crucial for the sense of smell. Olfactory receptors are specialized G-protein-coupled receptors (GPCRs) that detect odorant molecules in the nasal epithelium, triggering a cascade of neuronal responses that lead to smell perception. These receptors share a common structure with other GPCRs, featuring a 7-transmembrane domain, and are responsible for the recognition and G protein-mediated transduction of odorant signals. The activation of these receptors leads to various intracellular events, typically involving the modulation of second messengers such as cyclic AMP (cAMP). The challenge in inhibiting Olfr678 lies in the complexity of GPCR signaling pathways and the lack of specific direct inhibitors. Therefore, the focus is on indirect inhibitors that modulate related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists, such as propranolol, atenolol, and metoprolol, reduce cellular cAMP levels, which are crucial in GPCR signaling. This reduction in cAMP could indirectly affect the signaling pathways of GPCRs like Olfr678. Calcium channel blockers, including nifedipine and verapamil, alter intracellular calcium levels, another key factor in GPCR signaling. Changes in calcium dynamics can indirectly influence the function of GPCRs, including olfactory receptors like Olfr678.
Additionally, antagonists of angiotensin II receptors, such as losartan and candesartan, offer another approach to indirectly modulate olfactory receptor function. These antagonists may alter the GPCR signaling landscape, potentially affecting the function of receptors like Olfr678. Alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine might also indirectly impact the signaling mechanisms of GPCRs, including olfactory receptors. In summary, the indirect inhibition of Olfr678 involves a comprehensive understanding of GPCR biology and the interconnected nature of cellular signaling pathways. The chemicals listed provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr678. While direct inhibition remains a significant challenge, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, reduces cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr678. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, which could indirectly influence GPCR signaling pathways and impact Olfr678 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially influencing Olfr678. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and Olfr678 indirectly. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially affecting Olfr678. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr678. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr678. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr678. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr678. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr678. | ||||||